Cellular Immunotherapy Treatment Antigen-Directed for EBV Lymphoma (CITADEL)
A Phase 2 Single Arm Study to Investigate the Efficacy of Autologous EBV-specific T-cells for the Treatment of Patients With Aggressive EBV Positive Extranodal NK/T-cell Lymphoma (ENKTCL)
Sponsor: Cell Medica Ltd
Terminated
Insufficient enrollment rate
Other terminated trials from Cell Medica Ltd
More terminations from Cell Medica Ltd
A PHASE2 clinical study on EBV and Lymphoma, Extranodal NK-T-Cell, this trial is terminated or withdrawn. The trial is conducted by Cell Medica Ltd and has accumulated 11 data snapshots since 2014. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
11 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE2
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Apr 2019 — Jan 2021 [monthly]
Terminated PHASE2
▶ Show 6 earlier versions
-
Feb 2019 — Apr 2019 [monthly]
Terminated PHASE2
Status: Recruiting → Terminated
-
Jun 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jun 2017 — Jun 2018 [monthly]
Recruiting PHASE2
-
May 2017 — Jun 2017 [monthly]
Recruiting PHASE2
-
Feb 2017 — May 2017 [monthly]
Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Recruiting PHASE2
First recorded
Sep 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Cell Medica Ltd
For direct contact, visit the study record on ClinicalTrials.gov .